Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival

SIMPLE SUMMARY: Synthetic lethality approaches to cancer therapy involves combining events to cause cancer cell death. Using this strategy, major advances have occurred in the treatment of women with ovarian cancer who have defects in the Homologous Recombination Repair (HRR) pathway. When the HRR p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Tao, Dickson, Kristie-Ann, Yee, Christine, Ma, Yue, Ford, Caroline E., Bowden, Nikola A., Marsh, Deborah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563432/
https://www.ncbi.nlm.nih.gov/pubmed/36230543
http://dx.doi.org/10.3390/cancers14194621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563432/
https://www.ncbi.nlm.nih.gov/pubmed/36230543
http://dx.doi.org/10.3390/cancers14194621

Ejemplares similares